Multidisciplinary, respectful care of patients with GU cancers
Dr. William Oh, an expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers, is Chief of the Division of Hematology and Medical Oncology and Associate Director for Clinical Research for The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Tisch Cancer Institute received the prestigious NCI-designation in 2015. Dr. Oh's research interests include novel biomarkers and therapeutics in advanced prostate cancer. A leading investigator in the use of systemic treatments for prostate cancer, he has served as the principal investigator of multiple clinical trials in prostate and other GU cancers. In addition, he developed large clinical databases and specimen repositories for GU cancers at both Harvard and Mount Sinai which have enrolled over 8,000 patients with prostate, renal and bladder cancer over the past decade.
Dr. Oh has authored more than 250 original articles, reviews and book chapters on topics relating to prostate, renal, bladder and testicular cancers. He has edited 3 books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS) and the American Urological Association (AUA), including the Guidelines Committee for Castration Resistant Prostate Cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits "Testicular Cancer" for Up to Date and is Associate Editor of CA, A Cancer Journal for Clinicians. He was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors and Super Doctors.
Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women's Hospital in Boston. Dr. Oh subsequently completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997.
Prior to joining Mount Sinai in 2009, Dr. Oh was at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA for 14 years. He served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center.